Physician profile
Robert Michael Izor
NPI 1164409108
$36,316.79
in general payments reported to CMS, 2019-2025
40 companies · $6,829 in 2025
The $6,829 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,774 · 2021: $2,102 · 2022: $2,157 · 2023: $3,985 · 2024: $3,729 · 2025: $6,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,960 · Food and Beverage: $4,835 · Travel and Lodging: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,960.00 |
| Food and Beverage | $4,834.51 |
| Travel and Lodging | $748.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $13,939.40 | 2019-2020 | |
| Abbott Laboratories | $12,104.29 | 2019-2025 | Infinity |
| Acadia Pharmaceuticals INC | $1,535.67 | 2019-2025 | Nuplazid |
| Abbvie INC. | $1,500.72 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,052.29 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Mdd US Operations, LLC | $661.70 | 2019-2025 | Gocovri, Gocovri |
| Ipsen Biopharmaceuticals, INC | $628.07 | 2019-2024 | Dysport |
| Neurocrine Biosciences, INC. | $578.67 | 2019-2023 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $514.80 | 2019-2025 | Nourianz |
| Amneal Pharmaceuticals LLC | $396.56 | 2021-2025 | Rytary, Crexont, Lioresal (Baclofen) |
| Acorda Therapeutics, INC | $367.18 | 2019-2023 | Inbrija |
| Adamas Pharmaceuticals, INC. | $332.42 | 2019-2021 | |
| Ge Healthcare | $259.03 | 2019-2023 | |
| Medtronic, INC. | $253.80 | 2021-2025 | Percept PC Brainsense |
| Boston Scientific Corporation | $208.27 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Izor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.